CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

iguratimod

Small moleculeexperimental

Iguratimod is an anti-inflammatory small molecule drug used for the treatment of rheumatoid arthritis, together with methotrexate in Japan and China. As of 2015 the biological target was not known, but it prevents NF-κB activation and subsequently selectively inhibits COX-2 and several inflammatory cytokines. — Wikipedia

Clinical trial activity

27 trials · 23 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
9
Phase 3
4
Phase 4
12

Earliest trial started Jul 1, 2009 (NCT00965757)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1
Mol. weight
374.37 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-formylamino-7-methylsulfonylamino-6-phenoxy-4h-1-benzopyran-4-one
  • careram
  • iguratimod
  • iguratimod
  • iguratimod
  • iguratimod
  • iguratimod
  • iguratimod
  • iguratimod
  • kolbet
  • t 614
  • t 614
  • t-614
  • t-614
  • t-614
  • t-614

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07115641N/AAug 11, 2025China Academy of Chinese Medical Sciences, Henan University of Traditional Chinese Medicine, Jiao Tong University, Shandong University of Traditional Chinese Medicine
NCT06945666Phase 4Aug 1, 2025Zhejiang University
NCT07057778Phase 2Jul 1, 2025Capital Medical University, Government of China, Peking University
NCT06244628Phase 3Jan 10, 2024Xuzhou Medical University
NCT05803135Phase 4Mar 31, 2023Simcere Pharmaceutical Co., Ltd, Southern Medical University
NCT05789030N/AJul 1, 2022Chinese Academy of Medical Sciences
NCT05216757Phase 2/Phase 3 (Phase 3)Mar 31, 2022Peking University
NCT05302024Phase 2Mar 22, 2022Peking University
NCT05626348Phase 4Dec 22, 2021Shandong University
NCT05281068Phase 2Sep 1, 2021Capital Medical University, Chongqing Medical University, Peking University, Shanxi Bethune Hospital, Zhengzhou University
NCT04981145Phase 4Jul 31, 2021Zhejiang University
NCT06146972Phase 4Jun 1, 2021Shandong Province Qianfoshan Hospital
NCT04830644Phase 2Mar 22, 2021Simcere Pharmaceutical Co., Ltd
NCT04515706N/AJan 1, 2021Jiao Tong University
NCT04928066Phase 4Mar 1, 2020Shandong University
NCT03660059Phase 3Sep 30, 2018Astellas
NCT03368274Phase 4Sep 1, 2017Chinese Academy of Medical Sciences
NCT03054545N/AMay 8, 2017Jiao Tong University
NCT02936375Phase 2Mar 1, 2017Jiao Tong University
NCT03023592Phase 1/Phase 2 (Phase 2)Feb 1, 2017Tsinghua University
Showing 20 of 27 trials
Page 1 / 2

Organizations

Research & Development (23)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Simcere Pharmaceutical Co., LtdFor profit6522012
Jiao Tong UniversityAcademic/Hospital5332012
Peking UniversityAcademic/Hospital5432012
Shandong UniversityAcademic/Hospital3312017
Capital Medical UniversityAcademic/Hospital2012021
Chinese Academy of Medical SciencesAcademic/Hospital2222017
Zhejiang UniversityAcademic/Hospital2212021
AstellasFor profit1112018
China Academy of Chinese Medical SciencesAcademic/Hospital1112025
Chongqing Medical UniversityAcademic/Hospital1012021
EisaiFor profit1112009
Government of ChinaGovernment1012025
Henan University of Traditional Chinese MedicineAcademic/Hospital1012025
Nanjing Medical UniversityAcademic/Hospital1112016
Shandong Province Qianfoshan HospitalAcademic/Hospital1112021
Shandong University of Traditional Chinese MedicineAcademic/Hospital1012025
Shanxi Bethune HospitalAcademic/Hospital1012021
Southern Medical UniversityAcademic/Hospital1112023
Sun Yat-Sen UniversityAcademic/Hospital1012012
ToyamaFor profit1012009
23 organizations
Page 1 / 2